Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]raclopride

Movement Disorders

Volumn 12, Issue 1, 1997, Pages 33-38

  Antonini, Angelo ^a   Schwarz, Johannes ^c   Oertel, Wolfgang H ^c   Pogarell, Oliver ^c   Leenders, Klaus L ^a,b  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

11C raclopride; Dopamine D2 receptors; Parkinson's disease; Positron emission tomography

Indexed keywords

CARBON 14; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; RACLOPRIDE;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG UPTAKE; FEMALE; HUMAN; LONG TERM CARE; MALE; MOTOR DYSFUNCTION; NEUROTOXICITY; NORMAL HUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING;

AGED; ANTIPARKINSON AGENTS; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEURAL PATHWAYS; PARKINSON DISEASE; PUTAMEN; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031031846     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120107     Document Type: Article

References (23)

1. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanism, part II. Ann Neural 1988;24:372-378.
2. Rinne UK, Laihinen A, Rinne JO, Någren K, Bergman J, Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990;5:55-59.
3. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with [11C]raclopride and positron emission tomography. Ann Neural 1992;31:184-192.
4. Leenders KL, Antonini A, Meinck HM, Weindl A. Striatal dopamine D2 receptors in dopa-responsive dystonia and Parkinson's disease. In: Segawa M, Nomura:Y, eds. Age-related dopamine-dependent disorders. 1995:95-100.
5. Antonini A, Vontobel P, Psylla M, et al. Complementary PET studies of the striatal dopaminergic system in Parkinson's disease. Arch Neural 1995;52:1183-1190.
6. Antonini A, Schwarz J, Oertel WH, Beer HG, Madeja UD, Leenders KL. [11C]Raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-Dopa and lisuride therapy on striatal dopamine D2 receptors. Neurology 1994;44:1325-1329.
7. Antonini A, Leenders KL, Reist H, et al. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and [11C]raclopride. Arch Neural 1993;50:474-480
8. Guttman M, Seeman P. L-DOPA reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum. J Neural Transm 1985;64:93-103.
9. Ahlskog JE, Richelson E, Nelson A, et al. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients. Ann Neural 1991;30:185-191.
10. Griffiths PD, Perry RH, Crossman AR. A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neurosci Lett 1994;169:68-72.
11. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing off fluctuations in Parkinson's disease: contribution of post-synaptic mechanisms. Ann Neurol 1994;36:27-31.
12. Grandas F, Gancher ST, Rodriguez M, et al. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease. Clin Neuropharmacol 1992;15:13-18.
13. Leenders KL, Antonini A. PET [18F]fluorodopa uptake and disease progression in Parkinson's disease. Neurology 1995;45(suppl 5):A220.
14. Morrish PK, Sawle GV, Brooks DJ. The rate of progression in recent onset and advanced Parkinson's disease studied with [18]F-dopa positron emission tomography. J Neurol 1995;242(suppl 2):S15.
15. Leenders KL, Aquilonius SM, Hartvig P, et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res 1988;455:61-67.
16. Perlmutter JS, Kilboum MR, Raichle ME, Welch MJ. MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. Neurology 1987;37:1575-1579.
17. Farde L, Hall H, Pauli S, Halldin C. Variability in dopamine D2 receptor density and affinity: a PET study with [11C]raclopride in man. Synapse 1995;20:200-208.
18. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.
19. Volkow ND, Fowler JS, Wang GJ, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 1993;34:609-613.
20. Reches A, Wagner HR, Jackson-Lewis V, Yablonskaya-Alter E, Fahn S. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. Neurology 1984;34:1208-1212.
21. Jenner P, Boyce S, Marsden CD. Receptor changes during chronic dopaminergic stimulation. J Neural Transm Suppl 1988;27:161-175.
22. Tedroff J. Parkinson's disease: pathophysiology and PET [Doctorial thesis]. Acta Universitatis Upsaliensis, Uppsala, 1990.
23. Doudet DJ, Chan G, Dobko T, et al. In vivo binding of [11C]raclopride in asymptomatic and symptomatic long term MPTP treated rhesus monkeys by PET. J Cereb Blood Flow Metab 1995;15(suppl 1):S757.